CytomX attracts $70 mln Series D
South San Francisco-based CytomX, a developer of Probody therapeutics that treat cancer, has raised $70 million in Series D funding. Fidelity Management & Research Company led the round with participation from other investors that included Casdin Capital, Cormorant Asset Management, Deerfield Management, Perceptive Advisors, Redmile Group, Tekla Healthcare Investors and Tekla Life Sciences Investors, Venrock Healthcare Capital Partners and Wellington Management Company.
17 June 2015•2 mins read
